603results about "Tetracycline active ingredients" patented technology

The invention relates to a preparation method of an efficient antibacterial material based on bionic design. The method comprises the following steps: step A, synthesizing a piezoelectric antibacterial material; and step B, combining the piezoelectric antibacterial material and a targeting material through a liposome carrier to prepare a bionic bacteriophage. According to the scheme, an innovative bionic bacteriophage concept is provided, a simple and intelligent antibacterial system is developed, reactive oxygen species (ROS) in a bacterial microenvironment is stimulated to be improved through energy conversion, bacterial cell membranes, protein and DNA are destroyed, and therefore antibacterial treatment is carried out.

Provided herein are engineered nucleic acids (e.g., expression vectors, including viral vectors, such as lentiviral vectors, adenoviral vectors, AV vectors, herpes viral vectors, and retroviral vectors) that encode OCT4; KLF4; SOX2; or any combination thereof that are useful, for example, in inducing cellular reprogramming, tissue repair, tissue regeneration, organ regeneration, reversing aging, or any combination thereof. Also provided herein are recombinant viruses (e.g., lentiviruses, alphaviruses, vaccinia viruses, adenoviruses, herpes viruses, retroviruses, or AAVs) comprising the engineered nucleic acids (e.g., engineered nucleic acids), engineered cells, compositions comprising the engineered nucleic acids, the recombinant viruses, engineered cells, engineered proteins, chemical agents that are capable of activating expression of OCT4; KLF4; SOX2; or any combination thereof, an engineered protein selected from the group consisting of OCT4; KLF4; SOX2; or any combination thereof, an antibody capable of activating expression of OCT4; KLF4; SOX2; or any combination thereof, and methods of treating a (e.g., ocular disease), preventing a disease (e.g., ocular disease), regulating (e.g., inducing or inducing and then stopping) cellular reprogramming, regulating tissue repair, regulating tissue regeneration, or any combination thereof).

Provided herein are engineered nucleic acids (e.g., expression vectors, including viral vectors, such as lentiviral vectors, adenoviral vectors, AAV vectors, herpes viral vectors, and retroviral vectors) that encode OCT4; KLF4; SOX2; or any combination thereof that are useful, for example, in inducing cellular reprogramming, tissue repair, tissue regeneration, organ regeneration, reversing aging, or any combination thereof. Also provided herein are recombinant viruses (e.g., lentiviruses, alphaviruses, vaccinia viruses, adenoviruses, herpes viruses, retroviruses, or AAVs) comprising the engineered nucleic acids (e.g., engineered nucleic acids), engineered cells, compositions comprising the engineered nucleic acids, the recombinant viruses, engineered cells, engineered proteins, chemical agents that are capable of activating expression of OCT4; KLF4; SOX2; or any combination thereof, an engineered protein selected from the group consisting of OCT4; KLF4; SOX2; or any combination thereof, an antibody capable of activating expression of OCT4; KLF4; SOX2; or any combination thereof, and methods of treating a (e.g., ocular disease), preventing a disease (e.g., ocular disease), regulating (e.g., inducing or inducing and then stopping) cellular reprogramming, regulating tissue repair, regulating tissue regeneration, or any combination thereof).

Provided herein are methods for making liposomal API formulations via continuous in-line diafiltration processes. Also provided herein are liposomal API formulations manufactured by the disclosed methods.

The invention discloses a preparation method of omasycine tosylate for injection, and belongs to the technical field of pharmaceutical preparations. The preparation method of the olmacycline tosylate for injection comprises the following steps: filtering a mixture solution containing the olmacycline tosylate, the cane sugar, the pH regulator and the water for injection, filling and sealing, and freeze-drying to obtain the olmacycline tosylate for injection. According to the preparation method, the problem that in the prior art, intermediate product liquid medicine is not completely dissolved is solved, the prepared freeze-dried product is free of the problems of atrophy, collapse, bottom sticking, layering and the like, the preparation method is simple, easy to operate and reliable, the obtained freeze-dried product is low in moisture content and impurity content, the stability is improved, and the product quality is guaranteed.

Formulation of ectoparasiticidal and antibiotic “compositions into pharmaceutical compositions useful for the treatment of eyelid inflammation, in particular demodex related blepharitis and eye crusting.

Provided herein are pharmaceutical formulations and pharmaceutical compound salts which utilize complexing agents as counterions. Such formulations and salts are useful for treating a variety of disease and disorders. Provided herein are also treatment methods using the pharmaceutical compounds, pharmaceutical compositions, and pharmaceutically acceptable salts of the present disclosure.

The present invention discloses a drug conjugate based on ε-poly-L-lysine, its intermediate and its use. The present invention provides an ε-poly-L-lysine derivative-drug conjugate compound having a controllable number of group bonds and a controllable number of group bond sites as shown in formula (I). The drug conjugate of the present invention has one or more advantages of low renal clearance, low hepatic clearance and low splenic clearance, long plasma half-life, rapid accumulation of effective drug concentration in the lesion, and better therapeutic effect. [Case 1] TIFF2024542139000558.tif28169

The invention discloses an oxytetracycline injection and a preparation method thereof, and relates to the technical field of pharmaceutical preparations, the oxytetracycline is firstly micronized, then sprayed with water, frozen, heated and dried, soaked in a solution containing a surfactant, taken out and dried, and pretreated oxytetracycline is obtained; s2, water for injection is taken and heated, an antioxidant is added for dissolution, then a complexing agent is added, stirring is performed for dissolution, and a first solution is obtained; adding an organic solvent into the first solution, heating, adding the pretreated oxytetracycline, stirring and dissolving to obtain a second solution; adding a stabilizer into the second solution, and adjusting the pH value; and then supplementing the water for injection to obtain the injection. The oxytetracycline raw medicine powder is micronized to a specific particle size range, then freeze drying is performed to make the oxytetracycline raw medicine powder loose and porous, and compatibilization of the surfactant is further combined, so that the solubility and the stability of the oxytetracycline raw medicine powder are greatly improved in the subsequent injection preparation process.

The invention discloses a degradable nanocellulose sustained-release drug-loaded film and a preparation method thereof, and belongs to the technical field of drug functional materials. The preparation method comprises the following steps: mixing and stirring microcrystalline cellulose and 64wt% sulfuric acid solution, centrifuging, dialyzing to be neutral, and freeze-drying to obtain CNCs; cNCs, NaIO4 and water are mixed and then subjected to a light-shielding reaction, ethanol precipitation is added, dialysis purification is conducted, freeze drying is conducted, and formylation modified CNCs are obtained; mixing and stirring the aldehyde modified CNCs, sericin, polyvinyl alcohol, water and a target drug to obtain a core layer solution; dissolving a polylactic acid-glycolic acid copolymer into a mixed solution of chloroform and DMF (Dimethyl Formamide) to obtain a shell solution; the core layer solution and the shell layer solution are subjected to coaxial electrostatic spinning forming to obtain the drug-loaded fiber, then the drug-loaded fiber is subjected to biomimetic mineralization surface modification to obtain the degradable nanocellulose sustained-release drug-loaded film, the drug loading rate is increased, the mechanical property of the drug-loaded film is improved, and the sustained-release and release-controllable effects are achieved.

The invention relates to a silicon-based nano material for targeted therapy of brucellosis as well as a preparation method and application of the silicon-based nano material. The invention relates to a preparation method of a silicon-based nano material for targeted therapy of brucellosis. The preparation method comprises the following steps: (1) preparing magnetic mesoporous silica; (2) aminating the magnetic mesoporous silica, and modifying the magnetic mesoporous silica with a responsive material and yeast beta-glucan to obtain modified magnetic mesoporous silica; and (3) carrying out antibiotic loading on the modified magnetic mesoporous silica. According to the silicon-based nano material for targeted therapy of brucellosis as well as the preparation method and the application of the silicon-based nano material, the surface of magnetic macroporous mesoporous silica is modified with yeast beta-glucan capable of targeting M cells and glutathione responsive molecules, and a drug delivery system sensitive to a brucellosis environment is synthesized; the nano-carrier has targeted targeting selectivity for delivering and releasing drugs, the activity, slow release and target cell uptake efficiency of antibiotics are ensured, and the brucellosis treatment is more accurate and efficient.

Provided herein are methods for treating a pulmonary infection in a patient in need thereof, for example, a nontuberculous mycobacterial pulmonary infection for at least one treatment cycle. The method comprises administering to the lungs of the patient a pharmaceutical composition comprising a liposomal complexed aminoglycoside comprising a lipid component comprising electrically neutral lipids and an aminoglycoside. Administration comprises aerosolizing the pharmaceutical composition to provide an aerosolized pharmaceutical composition comprising a mixture of free aminoglycoside and liposomal complexed aminoglycoside, and administering the aerosolized pharmaceutical composition via a nebulizer to the lungs of the patient. The methods provided herein result in a change from baseline on the semi-quantitative scale for mycobacterial culture for a treated patient, and / or NTM culture conversion to negative during or after the administration period.

Provided herein are methods for making liposomal API formulations via continuous in-line diafiltration processes. Also provided herein are liposomal API formulations manufactured by the disclosed methods.

The invention discloses doxycycline hydrochloride and potassium clavulanate powder for aquatic products as well as a preparation method and application of the doxycycline hydrochloride and potassium clavulanate powder, and belongs to the technical field of biology. The doxycycline hydrochloride and the potassium clavulanate are combined for use, so that the antibacterial ability of the aquatic animals on drug-resistant bacteria can be enhanced, and various diseases of the aquatic animals caused by the drug-resistant bacteria can be better treated. It is further proved through experiments that potassium clavulanate can greatly reduce the drug resistance of bacteria and enhance the antibacterial activity of doxycycline hydrochloride. The doxycycline hydrochloride and the potassium clavulanate are combined to prepare the compound powder, the preparation process is simple, the raw materials are easy to obtain, and the compound powder is suitable for industrial large-scale production. When the compound powder is applied to treatment of aquatic animal diseases, the effect of the compound powder in treatment of aquatic animal bacterial infection diseases is verified through a challenge experiment. Wide application prospects are realized.

The invention discloses a preparation method of olmacycline tosylate for injection, belongs to the technical field of pharmaceutical preparations, and provides a special preparation and a preparation method of the olmacycline tosylate for injection in order to solve the problems that the olmacycline tosylate for injection is prone to epimerization and oxidative degradation and the room temperature stabilization time is short after redissolution. According to the preparation, omagazines tosylate is used as a main component and matched with glycerol, vitamin C, thioglycerol, sodium acetate and water for injection, and the pH is adjusted to a proper range through hydrochloric acid or sodium hydroxide. According to the method, by means of the synergistic effect of glycerin and vitamin C, glycerin fixes medicine molecules and protects vitamin C, vitamin C removes oxidation inducements, and thioglycerin is matched to assist in inhibiting degradation, so that the medicine stability is greatly improved, the redissolved liquid medicine can be stabilized at 25 DEG C for 72 hours, the total impurities are controlled at a low level, and the clinical actual requirements are met.

Devices, systems, and methods for combinatorial treatment of a condition with an implantable damping device and therapeutic agent are disclosed herein. Methods for treating one or more effects of the condition, such as a neurological condition, include providing the implantable damping device and at least one other therapy, such as a therapeutic agent, that treats the condition to the patient. The implantable damping device includes a flexible damping member and an abating substance and can be placed in apposition with a blood vessel. The flexible damping member forms a generally tubular structure having an inner and an outer surface, the inner surface formed of a sidewall having a partially deformable portion. The abating substance is disposed within the partially deformable portion and moves longitudinally and / or radially within the partially deformable portion in response to pulsatile blood flow.

Methods of treating a health condition by standardizing patients and donors with pre-treatment protocols to enhance the effects of probiotic administration, improving preservation steps of samples handled, and selecting best matching donors for selection for probiotic administration to effectively treat the health condition.

The present invention relates to a cannabidiol (CBD) type cannabinoid compound for use as a medicament. The CBD-type cannabinoid, cannabidiol-C6 (CBD-C6), is a naturally occurring cannabinoid that can be found in minor quantities in the cannabis plant. Furthermore, the cannabinoid can be produced by synthetic means and a method for the production of CBD-C6 is described herein. In addition, disclosed herein are data which demonstrate the efficacy of CBD-C6 in models of disease.

Provided herein are methods for treating a pulmonary infection in a patient in need thereof, for example, a nontuberculous mycobacterial pulmonary infection for at least one treatment cycle. The method comprises administering to the lungs of the patient a pharmaceutical composition comprising a liposomal complexed aminoglycoside comprising a lipid component comprising electrically neutral lipids and an aminoglycoside. Administration comprises aerosolizing the pharmaceutical composition to provide an aerosolized pharmaceutical composition comprising a mixture of free aminoglycoside and liposomal complexed aminoglycoside, and administering the aerosolized pharmaceutical composition via a nebulizer to the lungs of the patient. The methods provided herein result in a change from baseline on the semi-quantitative scale for mycobacterial culture for a treated patient, and / or NTM culture conversion to negative during or after the administration period.

The application provides a multifunctional nano particle for targeting abdominal aortic aneurysm and a preparation method and application thereof, and belongs to the field of nanobiomedicine, wherein polyphenol oxidation self-polymer nanoparticles are used as carriers, doxycycline is loaded, and a targeting ligand cRGD is modified on the surface of the nano carrier; the neovasculature in the media and adventitia of AAA sites helps accumulation of the nanoparticles in the abdominal aortic aneurysm, and the integrin αν3 beta receptor highly expressed on the surface of the diseased cell membrane can recognize the cRGD with high affinity, and then mediate the targeted endocytosis of the nanoparticles; after intravenous injection, the nanoparticles can be effectively enriched in the lesion site and achieve long-term retention, and can release DC in response to the high ROS level in the tumor microenvironment; the drug is rapidly released to take effect, and the non-specific toxic side effects are reduced; the free radical scavenging capacity of the nanoparticles can be synergized with the DC activity to treat AAA through multiple mechanisms such as anti-inflammatory, antioxidant, macrophage repolarization promotion, anti-apoptosis and calcification inhibition, and MMPs inhibition.

The present invention relates to a pharmaceutical composition for use against Gram-negative bacteria comprising at least one efflux pump inhibitor and at least one antibiotic. The invention also relates to the use of said pharmaceutical composition for resisting microorganisms, in particular bacteria, in particular gram-negative bacteria.

The present disclosure generally relates to compounds that bind to lysophosphatidic acid receptor 1 (LPAR1) and act as antagonists of LPAR1. The present disclosure also relates to the use of these compounds for the preparation of medicaments for treating diseases and / or conditions (including fibrosis and liver diseases such as non-alcoholic steatohepatitis (NASH)) by binding to LPAR1.

The present invention relates to a compound of formula (I) or formula (II) formula (I) formula (II) or a salt thereof for use in treating or preventing a viral disease or viral infection, wherein within formula (I) or (II) (A) A is H or OH, X is CH3, and R1 and R2 are H and R3 is selected from the group consisting of a linear or branched C3 to C8 alkyl, a cycloalkyl, an alkenyl, a phenylalkenyl (preferably styryl), an aryl, and a heteroaryl; or (B) A is H or OH, X is CH3, and R2 is H and R1 and R3 are independently selected from the group consisting of a linear or branched C3 to C8 alkyl, a cycloalkyl, an alkenyl, a phenylalkenyl (preferably styryl), an aryl, and a heteroaryl; or (C) A is H or OH, X is H or CH3, and R1 to R3 are each independently selected from H, F, Cl, Br, or I, provided that at least one of R1 to R3 is F, Cl, Br, or I; or wherein within formula (II) (D) A is H or OH, X is CH3, and R1 to R3 are H, and wherein for (A) and (B) the heteroatom of the heteroaryl is selected from S, O and N, and the linear or branched C3 to C8 alkyl, cycloalkyl, alkenyl, phenylalkenyl (preferably styryl), aryl, and heteroaryl are unsubstituted or are substituted, preferably substituted with one or more of F, Cl, Br, I, -OH, -SH, -NH2, -N3, -NO2, - CN, -CHO, -COOH, or -CONH2 and more preferably with one or more F or Br.

A heart valve prosthesis with one or more drug eluting mechanisms embedded in the prosthesis during manufacture.

The present invention relates to nucleic acids and modified immune cells or precursors thereof, comprising a first polynucleotide encoding an NF-κB p65-rTetO fusion protein comprising one or more transactivation domains (TAD) of human NF-κB p65 fused to a reverse Tet operator (rTetO) binding domain; a second polynucleotide comprising a Tet operator region (TetOR) for providing inducible expression of one or more transgene(s) operatively linked thereoto; and a third polynucleotide comprising a promoter directing transcription of p65-rTetO from a first strand of DNA, where the p65-rTetO is configured to induce transcription of a transgene of interest operatively linked to the TetOR in the presence of tetracycline or doxycycline (Dox) from an opposite strand of DNA.

Described herein is a method of diagnosing Lyme disease in a subject. The method includes determining a glycosylation profile of a protein whose glycosylation profile is associated with Lyme disease in a subject, and comparing the glycosylation profile of the protein with a predetermined glycosylation profile of the protein indicating free of Lyme disease or a predetermined glycosylation profile of the protein indicating Lyme disease. Further described herein is a method of treating and / or ameliorating Lyme disease in a subject. The method includes diagnosing Lyme disease in a subject and, if the subject is diagnosed to have Lyme disease, administering to the subject an effective amount of compound effective for treating Lyme disease. Further described herein is a method of evaluating a treatment for Lyme disease. The method includes comparing a glycosylation profile of the patient with glycosylation profiles associated with successful / unsuccessful treatments.

Provided herein are screening methods and animal models relevant to ocular diseases such as age-related macular degeneration (AMD), e.g., for use in identifying candidate therapeutics for treating or preventing ocular diseases such as AMD. Also provided herein are compounds / compositions useful for killing or inhibiting the growth of microorganisms such as Bacillus megaterium. Further provided herein are methods of using the compounds / compositions to treat infections with microorganisms such as Bacillus megaterium, as well as to treat or prevent diseases or conditions associated with such infections, such as AMD.

The present application relates to zinc-magnesium layered hydroxide nanoparticles as a drug delivery system for the treatment of periodontitis and / or peri-implantitis. The nanoparticles herein described have a layered hydroxide structure, have enhanced cell interaction and uptake, are biodegradable, efficient at drug loading, have an improved, pH-responsive drug release profile, and enhanced biological efficacy. The application also discloses a method to obtain the zinc-magnesium layered hydroxide nanoparticles.

The invention discloses a responsive drug-loaded polysaccharide / collagen polypeptide GTR sustained-release membrane and a preparation method thereof, and belongs to the technical field of oral biological materials. The preparation method comprises the following steps: oxidizing polysaccharide to prepare an oxidized polysaccharide solution; the oxidized polysaccharide is subjected to imidazole and cholesterol group grafting modification, antibacterial and anti-inflammatory drugs are loaded, and responsive drug-loaded nanoparticles are prepared; dissolving the determinated collagen polypeptide in normal saline to prepare a collagen polypeptide solution; and uniformly mixing the collagen polypeptide solution, the oxidized polysaccharide solution and the responsive drug-loaded polysaccharide nanoparticles to prepare the responsive drug-loaded polysaccharide / collagen polypeptide GTR sustained-release membrane. According to the invention, safe and nontoxic oxidized polysaccharide rich in carboxyl and aldehyde is used as a cross-linking agent, and responsive polysaccharide nanoparticles are introduced. The polysaccharide / collagen polypeptide GTR sustained-release membrane prepared by the invention has good biocompatibility, mechanical property, degradation property and long-acting response drug release capability, and can be applied to antibacterial treatment of periodontitis.